Brief: Sprint Bioscience Q3 Operating Loss Narrows To SEK 8.2 Mln
23/10/2019 06:37
Oct 23 (Reuters) - Sprint Bioscience AB SPRINT.ST :
* Q3 NET SALES SEK 4.4 MILLION VERSUS SEK 0 MILLION YEAR AGO
* Q3 OPERATING LOSS SEK 8.2 MILLION VERSUS LOSS SEK 8.9
MILLION
YEAR AGO
Source text for Eikon: ID:nWkrb5DXMS
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln